NICE flip-flops to recommend Novartis' Farydak; Novo incentives for plant may exceed $130M;

@FiercePharma: Flu expert warns against USDA move to build bird flu vaccine stockpile. Article | Follow @FiercePharma

@CarlyHFierce: @RepCummings to Shkreli: "To claim that a 50% discount after a 5,000% increase is a 'price cut' is Orwellian double-speak." | Follow @CarlyHFierce

> The U.K.'s cost watchdogs have changed their mind on Novartis' ($NVS) myeloma med Farydak, recommending the drug after initially rejecting it for NHS use earlier this year. Report

> Teva ($TEVA), which has agreed to purchase Allergan's ($AGN) generics unit for $40.5 billion, has priced its public offerings of American depositary shares and mandatory convertible preferred shares. Release

> A report raises concerns about drug company employees doing health screenings at "health camps" in India where they hand out free medications. Story

> The incentives Novo Nordisk ($NVO) will get from North Carolina for investing $1.8 billion into a plant there could exceed $130 million. Story

> AstraZeneca ($AZN) will close an API plant in Bengaluru, India. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Story | Follow @VarunSaxena2

@EmilyWFierce: Check out this week's Dx Digest, featuring liquid biopsy news from Guardant Health and Circulogene Theranostics. Report | Follow @EmilyWFierce

> Novartis weighs sale of contact lens business as Alcon unit struggles to chart growth. More

> U.K.'s NHS funds 1,000+ patient trial of a minimally invasive artificial lung. Story

Biotech News

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: This week we've been seeing the venture cash flowing. Bodes well for lots more action in 2016. | Follow @JohnCFierce

> True North adds crossover investors in its $40M Series C. Article

> Kuros to merge with Cytos to gain entry to the Swiss Stock Exchange. Report

> FierceBiotech Radio on Gilead's maxed-out revenue and BioMarin's FDA struggles. More | Subscribe

CRO News

> Medidata reaches into South Korea with a CRO partnership. News

> Parexel revamps its trial management system for drugmakers large and small. Report

> INC's financiers bank another $272M in the IPO afterglow. More

> Survey: CRO employee turnover soars amid an industry boom. Story

> Quotient Clinical snapped up by Gillings-founded buyout firm. Article

Pharma Manufacturing News

> Wockhardt says U.K. regulatory agency issued GMP certificate to troubled Chikalthana plant. News

> EU agency gives Baxalta green light to begin manufacturing two plasma-based therapies. Story

> Radiopharmaceutical manufacturer Iason Italia hit with noncompliance report. Article

> FDA cites two Endo subsidiaries for product recalls. Report

> Danaher acquires German quality inspection firm Laetus for undisclosed price. Item

Pharma Asia News

> India's GVK Bio gets infusion of cash from ChrysCapital. Item

> Generic drugs face April 2016 price caps in Japan. More

> Ascletis gets $20M from Goldman in race to China HCV approval. Report

> Singapore researchers close in on 'liquid biopsy' to track cancer progress, treatment. Story

> BMJ: Drugmakers get quid pro quo for participation in Indian health camps. Article

And Finally... Allergan CEO Brent Saunders, whose Ireland-based company just agreed to merge with Pfizer ($PFE), says his father gave him a hard time at Thanksgiving dinner for helping the pharma giant dodge higher U.S. taxes. More